Therefore, it can be considered that these immune cells, 19 checkpoint genes and 11 chemokine genes may participate in the development of HER2-positive breast cancer, providing reliable targets for immunotherapy of HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.